{"id":6920,"date":"2022-07-14T13:48:16","date_gmt":"2022-07-14T13:48:16","guid":{"rendered":"https:\/\/oncopeptides.com.haus.se\/investors\/aktien\/nyemissioner\/nyemission-2022\/"},"modified":"2026-03-19T15:45:33","modified_gmt":"2026-03-19T15:45:33","slug":"nyemission-2022","status":"publish","type":"investors","link":"https:\/\/oncopeptides.com.haus.se\/sv\/investerare\/aktien\/nyemissioner\/nyemission-2022\/","title":{"rendered":"Nyemission 2022"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"6920\" class=\"elementor elementor-6920 elementor-6775\" data-elementor-post-type=\"investors\">\n\t\t\t\t<style>\n                .elementor-element-9e812be{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-9e812be e-flex e-con-boxed e-con e-parent\" data-id=\"9e812be\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<style>\n                .elementor-element-b82416a{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-b82416a e-con-full haus-2-1 e-flex e-con e-child\" data-id=\"b82416a\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c600e1a elementor-widget elementor-widget-heading\" data-id=\"c600e1a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Nyemission<br><span style=\"color: var(--color-orange)\">2022<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bee73b7 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"bee73b7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-eb7a6e1{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-eb7a6e1 e-con-full e-flex e-con e-child\" data-id=\"eb7a6e1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-58c15ef elementor-widget elementor-widget-text-editor\" data-id=\"58c15ef\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides har genomf\u00f6rt en riktad nyemission om cirka 435,6 miljoner SEK (cirka 41,1 miljoner USD)<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d856ce1 elementor-widget elementor-widget-text-editor\" data-id=\"d856ce1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>14 juli 2022 \u2013 Regulatoriskt pressmeddelande<\/p><p>Styrelsen f\u00f6r Oncopeptides AB (publ) (&#8221;Oncopeptides&#8221; eller &#8221;Bolaget&#8221;) (Nasdaq Stockholm: ONCO) har beslutat att emittera 15 061 443 nya aktier (&#8221;De nya aktierna&#8221;) i en riktad nyemission till internationella och svenska institutionella investerare baserat p\u00e5 det bemyndigande som beviljades av \u00e5rsst\u00e4mman den 28 juni 2022 (&#8221;Den riktade nyemissionen&#8221;). Priset f\u00f6r de nya aktierna \u00e4r 28,92 SEK per ny aktie, vilket motsvarar st\u00e4ngningskursen p\u00e5 dagen f\u00f6r detta tillk\u00e4nnagivande av Oncopeptides-aktien, s\u00e5som handlad p\u00e5 Nasdaq Stockholm. Ett antal internationella och svenska investerare deltog i den riktade nyemissionen, inklusive nya investerare s\u00e5som Redmile Group, HealthCap VIII och Adrigo Asset Management, samt de befintliga aktie\u00e4garna HealthCap VI, Industrifonden och Swedbank Robur Fonder, med efterfr\u00e5gan p\u00e5 de nya aktierna som \u00f6versteg storleken p\u00e5 den riktade nyemissionen. Genom den riktade nyemissionen kommer Oncopeptides att erh\u00e5lla en emissionslikvid om cirka 435,6 miljoner SEK (cirka 41,1 miljoner USD) f\u00f6re transaktionskostnader.   <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b5606b9 elementor-widget elementor-widget-button\" data-id=\"b5606b9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com.haus.se\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-4356-msek-cirka-411-musd\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8410603 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"8410603\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":0,"parent":5698,"menu_order":0,"template":"","meta":{"_acf_changed":false},"protected-content":[341],"class_list":["post-6920","investors","type-investors","status-publish","hentry","protected-content-show-disclaimer"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/investors\/6920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/investors"}],"about":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/types\/investors"}],"version-history":[{"count":1,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/investors\/6920\/revisions"}],"predecessor-version":[{"id":6921,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/investors\/6920\/revisions\/6921"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/investors\/5698"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/media?parent=6920"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/protected-content?post=6920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}